We are thrilled to announce that our client, Exeliom Biosciences, has secured a significant investment from Forepont Capital Partners. This New York-based venture capital fund, known for funding in innovative healthcare companies, has invested in Exeliom Biosciences to accelerate their clinical advancements in immunotherapy.

At act Aston Avocats, we are committed to supporting the innovation and medical advancements of our clients.